ATE218164T1 - Hemmung der fortpflanzung von arterienglattmuskelzellen - Google Patents

Hemmung der fortpflanzung von arterienglattmuskelzellen

Info

Publication number
ATE218164T1
ATE218164T1 AT95912700T AT95912700T ATE218164T1 AT E218164 T1 ATE218164 T1 AT E218164T1 AT 95912700 T AT95912700 T AT 95912700T AT 95912700 T AT95912700 T AT 95912700T AT E218164 T1 ATE218164 T1 AT E218164T1
Authority
AT
Austria
Prior art keywords
reproduction
inhibition
smooth muscle
muscle cells
arterial smooth
Prior art date
Application number
AT95912700T
Other languages
English (en)
Inventor
Elizabeth G Nabel
Gary J Nabel
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22784770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE218164(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE218164T1 publication Critical patent/ATE218164T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AT95912700T 1994-03-21 1995-03-01 Hemmung der fortpflanzung von arterienglattmuskelzellen ATE218164T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/210,902 US6780406B1 (en) 1994-03-21 1994-03-21 Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
PCT/US1995/002646 WO1995025807A1 (en) 1994-03-21 1995-03-01 Inhibition of arterial smooth muscle cell proliferation

Publications (1)

Publication Number Publication Date
ATE218164T1 true ATE218164T1 (de) 2002-06-15

Family

ID=22784770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912700T ATE218164T1 (de) 1994-03-21 1995-03-01 Hemmung der fortpflanzung von arterienglattmuskelzellen

Country Status (7)

Country Link
US (2) US6780406B1 (de)
EP (1) EP0752002B1 (de)
JP (1) JP3778930B2 (de)
AT (1) ATE218164T1 (de)
CA (1) CA2184065C (de)
DE (1) DE69526853T2 (de)
WO (1) WO1995025807A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
GB9501142D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Compounds for use in medicine
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
IL125756A (en) 1996-02-15 2003-05-29 Biosense Inc Catheter for use in surgery
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6818016B1 (en) 1997-06-27 2004-11-16 The Regents Of The University Of Michigan Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo
EP1900818A3 (de) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neissersche Antigene
US6794369B2 (en) 1997-12-31 2004-09-21 Pharmasonics Methods, systems, and kits for intravascular nucleic acid delivery
WO1999033500A2 (en) 1997-12-31 1999-07-08 Pharmasonics, Inc. Methods, systems, and kits for intravascular nucleic acid delivery
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
AU772963B2 (en) * 1998-04-24 2004-05-13 Onyx Pharmaceuticals Adenoviral vectors for treating disease
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
EP2261347A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
CN1074459C (zh) * 1998-11-25 2001-11-07 马丁 重组腺病毒－胸苷激酶构建体及其获得方法和用途
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
CN1357050A (zh) * 1999-07-02 2002-07-03 昂尼克斯药物公司 用于治疗疾病的腺病毒载体
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1226253A2 (de) 1999-10-29 2002-07-31 Chiron S.P.A. Antigene peptide aus neisseria
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ATE439372T1 (de) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2168596B1 (de) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682728B1 (en) 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima

Also Published As

Publication number Publication date
DE69526853D1 (de) 2002-07-04
CA2184065C (en) 2007-06-12
JP3778930B2 (ja) 2006-05-24
US6780406B1 (en) 2004-08-24
JPH09511240A (ja) 1997-11-11
EP0752002B1 (de) 2002-05-29
WO1995025807A1 (en) 1995-09-28
US6979677B1 (en) 2005-12-27
EP0752002A1 (de) 1997-01-08
DE69526853T2 (de) 2003-01-16
CA2184065A1 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
DE69526853D1 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
NZ333373A (en) Use of amino acid derivatives for preparing compositions with improved multi-drug resistance activity
KR930009607A (ko) 증식성 질환의 치료를 위한 다이피리다몰
NO991951L (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
DE69731540D1 (de) Behandlung von diarrhoe
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
WO2000010613A3 (en) Inhibition of smooth muscle cell migration by heme oxygenase 1
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE69424732D1 (de) Verwendung eines imidazols zur herstellung eines medikamentes zur behandlung der arteriosklerose
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
PT1042315E (pt) Piridilalcano alceno e alcino carboxamidas imido-substituidas ciclicas uteis como agentes citoestacticos e imunossupressores
GR3036691T3 (en) Dna sequences related to isolated fragile x syndrome
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
HU895788D0 (en) Process for producing peptides and medical products containing them
DE69228813D1 (de) Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
MX9800622A (es) Agentes terapeuticos mejorados.
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
MY120530A (en) Combination preparation for use in dementia
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
AP9701142A0 (en) 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds.
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties